2 deoxy-D-glucose augments the mitochondrial respiratory chain in heart.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
27 04 2022
Historique:
received: 01 09 2021
accepted: 22 03 2022
entrez: 28 4 2022
pubmed: 29 4 2022
medline: 30 4 2022
Statut: epublish

Résumé

2-Deoxy-D-glucose (2DG) has recently received emergency approval for the treatment of COVID-19 in India, after a successful clinical trial. SARS-CoV-2 infection of cultured cells is accompanied by elevated glycolysis and decreased mitochondrial function, whereas 2DG represses glycolysis and stimulates respiration, and restricts viral replication. While 2DG has pleiotropic effects on cell metabolism in cultured cells it is not known which of these manifests in vivo. On the other hand, it is known that 2DG given continuously can have severe detrimental effects on the rodent heart. Here, we show that the principal effect of an extended, intermittent 2DG treatment on mice is to augment the mitochondrial respiratory chain proteome in the heart; importantly, this occurs without vacuolization, hypertrophy or fibrosis. The increase in the heart respiratory chain proteome suggests an increase in mitochondrial oxidative capacity, which could compensate for the energy deficit caused by the inhibition of glycolysis. Thus, 2DG in the murine heart appears to induce a metabolic configuration that is the opposite of SARS-CoV-2 infected cells, which could explain the compound's ability to restrict the propagation of the virus to the benefit of patients with COVID-19 disease.

Identifiants

pubmed: 35478201
doi: 10.1038/s41598-022-10168-1
pii: 10.1038/s41598-022-10168-1
pmc: PMC9044724
doi:

Substances chimiques

Proteome 0
Deoxyglucose 9G2MP84A8W
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6890

Subventions

Organisme : Medical Research Council
ID : MC_PC_13029/2
Pays : United Kingdom

Informations de copyright

© 2022. The Author(s).

Références

mBio. 2019 Mar 12;10(2):
pubmed: 30862747
Nat Genet. 2008 May;40(5):546-52
pubmed: 18443592
J Am Soc Nephrol. 2016 Jul;27(7):1958-69
pubmed: 26534924
J Biol Chem. 1957 Feb;224(2):963-9
pubmed: 13405925
IUBMB Life. 2014 Feb;66(2):110-21
pubmed: 24578297
Exp Neurol. 1999 Feb;155(2):302-14
pubmed: 10072306
Nat Methods. 2009 May;6(5):359-62
pubmed: 19377485
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Nature. 2020 Jul;583(7816):469-472
pubmed: 32408336
Cell Metab. 2018 Sep 4;28(3):463-475.e4
pubmed: 30184486
Toxicol In Vitro. 2013 Dec;27(8):2142-8
pubmed: 24055893
Nat Commun. 2018 Jul 26;9(1):2935
pubmed: 30050148
Cell Metab. 2020 Sep 1;32(3):437-446.e5
pubmed: 32697943
IUBMB Life. 2021 Oct;73(10):1198-1204
pubmed: 34418270
Mol Cell Proteomics. 2018 Dec;17(12):2534-2545
pubmed: 30385480
Nat Commun. 2021 Dec 6;12(1):6997
pubmed: 34873176
Nat Commun. 2021 Mar 25;12(1):1876
pubmed: 33767183
EMBO Mol Med. 2020 Dec 7;12(12):e13001
pubmed: 33078545
Talanta. 2018 Feb 1;178:362-368
pubmed: 29136834
Toxicol Appl Pharmacol. 2010 Mar 15;243(3):332-9
pubmed: 20026095
Virology. 1973 Apr;52(2):447-55
pubmed: 4350224
Nat Commun. 2021 Mar 15;12(1):1676
pubmed: 33723254

Auteurs

Irati Aiestaran-Zelaia (I)

Biodonostia Health Research Institute, 20014, San Sebastián, Spain.
Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Paseo de Miramón 182, 20014, San Sebastián, Spain.

María Jesús Sánchez-Guisado (MJ)

Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Paseo de Miramón 182, 20014, San Sebastián, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.

Marina Villar-Fernandez (M)

Biodonostia Health Research Institute, 20014, San Sebastián, Spain.

Mikel Azkargorta (M)

Proteomics Platform, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), CIBERehd, ProteoRed-ISCIII, Bizkaia Science and Technology Park, 48160, Derio, Spain.

Lucia Fadon-Padilla (L)

Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Paseo de Miramón 182, 20014, San Sebastián, Spain.

Uxoa Fernandez-Pelayo (U)

Biodonostia Health Research Institute, 20014, San Sebastián, Spain.

Diego Perez-Rodriguez (D)

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, Royal Free Campus, London, NW3 2PF, UK.

Pedro Ramos-Cabrer (P)

Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Paseo de Miramón 182, 20014, San Sebastián, Spain.
IKERBASQUE, Basque Foundation for Science, 48013, Bilbao, Spain.

Antonella Spinazzola (A)

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, Royal Free Campus, London, NW3 2PF, UK.

Félix Elortza (F)

Proteomics Platform, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), CIBERehd, ProteoRed-ISCIII, Bizkaia Science and Technology Park, 48160, Derio, Spain.

Jésus Ruíz-Cabello (J)

Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Paseo de Miramón 182, 20014, San Sebastián, Spain. jruizcabello@cicbiomagune.es.
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain. jruizcabello@cicbiomagune.es.
IKERBASQUE, Basque Foundation for Science, 48013, Bilbao, Spain. jruizcabello@cicbiomagune.es.
Departamento de Química en Ciencias Farmacéuticas, Facultad de Farmacia, Universidad Complutense de Madrid (UCM), Madrid, Spain. jruizcabello@cicbiomagune.es.

Ian J Holt (IJ)

Biodonostia Health Research Institute, 20014, San Sebastián, Spain. ian.holt@biodonostia.org.
Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, Royal Free Campus, London, NW3 2PF, UK. ian.holt@biodonostia.org.
IKERBASQUE, Basque Foundation for Science, 48013, Bilbao, Spain. ian.holt@biodonostia.org.
CIBERNED (Center for Networked Biomedical Research On Neurodegenerative Diseases, Ministry of Economy and Competitiveness, Institute Carlos III), 28031, Madrid, Spain. ian.holt@biodonostia.org.
Universidad de País Vasco, Barrio Sarriena S/N, 48940, Leioa, Bilbao, Spain. ian.holt@biodonostia.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH